Cowen Prime Services LLC raised its stake in Zoetis Inc. (NYSE:ZTS) by 0.1% during the second quarter, according to its most recent disclosure with the SEC. The fund owned 52,930 shares of the company’s stock after buying an additional 35 shares during the period. Zoetis accounts for 1.5% of Cowen Prime Services LLC’s portfolio, making the stock its 20th largest position. Cowen Prime Services LLC’s holdings in Zoetis were worth $3,302,000 as of its most recent filing with the SEC.

Several other hedge funds have also modified their holdings of ZTS. Assetmark Inc. boosted its stake in shares of Zoetis by 4.6% in the first quarter. Assetmark Inc. now owns 1,918 shares of the company’s stock valued at $102,000 after buying an additional 85 shares during the period. Guardian Life Insurance Co. of America boosted its stake in shares of Zoetis by 0.7% in the first quarter. Guardian Life Insurance Co. of America now owns 1,905 shares of the company’s stock valued at $102,000 after buying an additional 13 shares during the period. Point72 Asia Hong Kong Ltd acquired a new stake in shares of Zoetis during the first quarter valued at approximately $111,000. Advisory Services Network LLC acquired a new stake in shares of Zoetis during the first quarter valued at approximately $112,000. Finally, First Interstate Bank boosted its stake in shares of Zoetis by 3.5% in the first quarter. First Interstate Bank now owns 2,250 shares of the company’s stock valued at $120,000 after buying an additional 76 shares during the period. 92.70% of the stock is owned by institutional investors and hedge funds.

Zoetis Inc. (ZTS) opened at 61.33 on Friday. The company has a market capitalization of $30.00 billion, a price-to-earnings ratio of 34.67 and a beta of 1.02. Zoetis Inc. has a 12-month low of $46.86 and a 12-month high of $63.85. The firm’s 50-day moving average price is $61.83 and its 200 day moving average price is $58.45.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Tuesday, August 8th. The company reported $0.53 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.53. The firm had revenue of $1.27 billion during the quarter, compared to analysts’ expectations of $1.27 billion. Zoetis had a net margin of 17.50% and a return on equity of 62.49%. The business’s revenue was up 5.0% on a year-over-year basis. During the same period last year, the company earned $0.49 earnings per share. On average, equities research analysts expect that Zoetis Inc. will post $2.34 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Zoetis Inc. (ZTS) Stake Increased by Cowen Prime Services LLC” was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this news story on another website, it was illegally copied and republished in violation of US & international copyright & trademark law. The legal version of this news story can be read at https://www.thecerbatgem.com/2017/08/26/zoetis-inc-zts-stake-increased-by-cowen-prime-services-llc.html.

ZTS has been the subject of several recent analyst reports. Zacks Investment Research raised Zoetis from a “hold” rating to a “buy” rating and set a $67.00 target price for the company in a research report on Wednesday, May 10th. Jefferies Group LLC raised their target price on Zoetis from $65.00 to $70.00 and gave the stock a “buy” rating in a research report on Tuesday, May 9th. BMO Capital Markets reiterated a “buy” rating and set a $60.00 price objective on shares of Zoetis in a report on Thursday, May 4th. Argus reiterated a “buy” rating and set a $69.00 price objective (up from $60.00) on shares of Zoetis in a report on Tuesday, May 30th. Finally, CL King initiated coverage on Zoetis in a report on Friday, May 26th. They set a “buy” rating and a $71.00 price objective for the company. One research analyst has rated the stock with a sell rating, five have issued a hold rating and twelve have assigned a buy rating to the company. Zoetis presently has a consensus rating of “Buy” and a consensus price target of $64.78.

About Zoetis

Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS).

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Stock Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related stocks with our FREE daily email newsletter.